Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.37 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5851779 | 0.88 | TDP1 (0.36) | KMT2AMDM2CTDSP1TDP1 | |
| SCHEMBL5852692 | 0.84 | KDM4E (0.32) | — | |
| SCHEMBL5852696 | 0.84 | KDM4E (0.32) | — | |
| SCHEMBL5853528 | 0.76 | — | — | |
| SCHEMBL5853534 | 0.76 | — | — | |
| SCHEMBL6829838 | 0.75 | MDM2 (0.32) | KMT2AMDM2CTDSP1 | |
| SCHEMBL5852718 | 0.72 | HTR2A (0.48) | — | |
| SCHEMBL6997115 | 0.71 | PER2 (0.48) | KMT2AMDM2CTDSP1ATMMEN1 | |
| SCHEMBL6621027 | 0.71 | DRD3 (0.34) | KMT2AMEN1TDP1 | |
| SCHEMBL6996046 | 0.69 | KDM4E (0.33) | KMT2AMEN1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7057036-B2 | Pyrrolothiazine and pyrrolothiazepine compounds having serotonin-2 receptor antagonistic and alpha-1-blocking action | DAIICHI SUNTORY PHARMA CO., LTD. (JP) | 2006-06-06 | — | — | US | disclosed |
| US-20050038242-A2 | PYRROLOTHIAZINE AND PYRROLOTHIAZEPHINE COMPOUNDS HAVING SEROTONIN-2 RECEPTOR ANTAGONISTIC AND ALPHA-1-BLOCKING ACTION | DAIICHI SUNTORY PHARMA CO., LTD. (JP) | 2005-02-17 | — | — | US | disclosed |
| US-20040127705-A1 | Pyrrolothiazine and pyrrolothiazepine compounds having serotonin-2 receptor antagonistic and alpha-1-blocking action | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-07-01 | — | — | US | disclosed |
| US-6624314-B2 | A pyrrolesulfonamide derivative or salt, useful for treating circulatory diseases such as ischemic heart diseases, cerebrovascular disturbances and peripheral circulatory disturtances | DAIICHI SUNTORY PHARMA CO., LTD. (JP) | 2003-09-23 | — | — | US | disclosed |
| US-20020040017-A1 | Pyrrolothiazine and pyrrolothiazepine compounds having serotonin-2 receptor antagonistic and alpha-1-blocking action | SUNTORY LIMITED (JP) | 2002-04-04 | — | — | US | disclosed |
| US-6271223-B1 | CARDIOVASCULAR DISORDERS | SUNTORY LIMITED (JP) | 2001-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038242-A2 | PYRROLOTHIAZINE AND PYRROLOTHIAZEPHINE COMPOUNDS HAVING SEROTONIN-2 RECEPTOR ANTAGONISTIC AND ALPHA-1-BLOCKING ACTION | HTR1D, HTR1E, TPH1 | KMT2A 3791/4885MDM2 2923/4885CTDSP1 1270/4885 |
| US-20040127705-A1 | Pyrrolothiazine and pyrrolothiazepine compounds having serotonin-2 receptor antagonistic and alpha-1-blocking action | TPH1, HTR1A, HTR1D | KMT2A 3086/4885MDM2 2088/4885CTDSP1 2597/4885 |
| US-20020040017-A1 | Pyrrolothiazine and pyrrolothiazepine compounds having serotonin-2 receptor antagonistic and alpha-1-blocking action | TPH1, HTR1A, HTR1D | KMT2A 3064/4885MDM2 2090/4885CTDSP1 2646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.